CD79A and COVID-19: Several studies have demonstrated that one of the best‐performing COVID‐19 vaccine regimens is ChAdOx1 prime followed by an mRNA boost with high spike‐specific broadly nAb, IgG, and IgA titers alongside CD4+ and CD8+ T cells.[43, 44, 45] The use of ChAdOx1‐delivered Gt1‐6‐E2Δ123 followed by an mRNA Gt1‐6‐E2Δ123 boost may prove to be an optimal regimen for the generation of HCV‐specific T‐ and B‐cell responses.